The Right to Try Act offers a federal pathway for patients with life-threatening illnesses to access investigational drugs outside clinical trials, but using it to obtain psychedelic therapies like psilocybin or MDMA remains legally complex and practically difficult. While the 2018 law allows patients who have exhausted approved treatments to request experimental medicines directly from manufacturers, it does not compel any company to say yes, and most psychedelic developers have been reluctant to supply therapies outside controlled research settings.
On April 18, 2026, President Trump signed an executive order directing the FDA and DEA to establish a Right to Try pathway specifically for psychedelic treatments targeting serious mental illness. This marks a significant shift in federal posture, but critical implementation details remain unresolved. The order does not automatically grant access, change the scheduling of psilocybin or MDMA under the Controlled Substances Act, or override existing manufacturer protocols.
For patients and caregivers searching for clarity, the reality is this: Right to Try eligibility hinges on a life-threatening diagnosis, exhaustion of approved options, inability to enroll in a trial, and a physician’s written support. But eligibility does not equal availability. Manufacturers control supply, and the April 2026 directive tasks federal agencies with creating facilitation mechanisms that do not yet exist.
This guide explains who qualifies under the Right to Try Act, how the 2026 executive order may alter psychedelic access, what practical and legal barriers remain, and what steps you can take now if you or a loved one are considering this route. We integrate the latest regulatory developments, compliance requirements, and harm-reduction principles to help you make informed, safer decisions.
What the Right to Try Act Actually Covers, and Who Qualifies
The Right to Try Act is a federal pathway, not a universal guarantee. Passed in 2018, it allows patients with life-threatening illnesses to request investigational drugs that haven’t yet received FDA approval, but only if they meet strict eligibility criteria and a manufacturer agrees to provide the treatment.
To qualify, you must have a disease or condition likely to cause death within months or a few years. You must have tried all FDA-approved treatments relevant to your condition, or determined with your physician that none exist. You also must be unable to participate in a clinical trial for the investigational drug. This might be because trials are full, not recruiting near you, or exclude you based on age, other health conditions, or prior treatment history.
The investigational drug itself must have completed at least a Phase I safety trial with the FDA. Phase I studies test basic safety and dosing in a small group of people, typically 20 to 80 participants, and represent the earliest stage of human testing. This requirement is critical: if a compound hasn’t finished Phase I, manufacturers legally cannot supply it under Right to Try, no matter how urgent the patient’s need.
Right to Try is entirely patient-initiated. Unlike expanded access (also called compassionate use), the FDA does not review or approve individual Right to Try cases. Manufacturers submit only an annual summary report to the agency listing how many patients received the drug, outcomes, and any adverse events. The FDA’s role is limited to receiving and publicly posting these summaries; it does not vet requests or intervene unless serious safety concerns emerge.
The biggest practical hurdle is manufacturer willingness. A company is under no obligation to provide its investigational product under Right to Try. It may decline due to limited supply, concerns about liability, the cost of producing uncompensated doses, or the risk that adverse outcomes could jeopardize FDA approval of the drug. For psychedelics, most of which remain Schedule I controlled substances, this reluctance is amplified by regulatory complexity, the need for specialized handling, and the scarcity of sponsors willing to navigate DEA and state-level restrictions.
The April 2026 Executive Order: What It Directs, and What It Doesn’t Guarantee
On April 18, 2026, President Donald Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness.” The order directs the FDA, HHS, DEA, and VA to take coordinated action to accelerate research, regulatory review, and patient access to psychedelic drugs as treatments for serious mental health conditions. Specifically, it instructs FDA and DEA to “facilitate and establish” a pathway for patients to access psychedelic therapies under the Right to Try Act.
The executive order is a directive to explore and develop policy, not a green light for immediate patient access. It requires federal agencies to coordinate and establish procedures, but it does not override existing Right to Try eligibility requirements or waive Schedule I classification barriers. Patients must still meet the Act’s life-threatening diagnosis threshold, have exhausted approved treatments, and be unable to participate in a clinical trial. The order also does not compel manufacturers to supply psychedelic therapies or guarantee that any specific compound will qualify under the pathway being developed.
As of September 2026, no formal guidance or implementation timeline has been published by FDA or DEA detailing how patients would request psychedelic therapies under this anticipated pathway. The agencies have not yet clarified which psychedelics would be eligible, what documentation would be required, or how Schedule I restrictions would be reconciled with Right to Try provisions. The order sets a policy direction, but the practical mechanics remain under development.
Which Psychedelics Could Qualify, and Why Most Don’t Yet
Right to Try requires an investigational drug to have completed at least Phase I safety trials and to have an active Investigational New Drug application with FDA. That’s the threshold. But investigational status alone doesn’t unlock access. The compound must be manufactured, the sponsor must be willing to supply it under Right to Try, and it must not pose insurmountable legal or regulatory barriers. For psychedelics, those conditions rarely align.
Psilocybin has advanced the furthest. Multiple companies have completed Phase II trials for treatment-resistant depression and are moving toward or through Phase III. It meets the Phase I completion requirement. However, psilocybin remains a Schedule I controlled substance, and only a handful of pharmaceutical-grade manufacturers exist. Most are focused on completing clinical trials and eventual FDA approval, not on supplying individual patients outside of trials. Manufacturer participation is voluntary, and few have signaled willingness to navigate the compliance and liability complexities of Right to Try.
MDMA (3,4-methylenedioxymethamphetamine) similarly completed Phase III trials for PTSD, and investigational formulations have cleared Phase I. Yet the same constraints apply: Schedule I status, limited pharmaceutical-grade supply, and sponsor reluctance. The executive order directs agencies to facilitate access, but it doesn’t compel manufacturers to participate or eliminate scheduling obstacles.
| Compound | Investigational Phase Status (2026) | DEA Schedule | Right to Try Feasibility |
|---|---|---|---|
| Psilocybin | Phase II/III (multiple sponsors) | Schedule I | Theoretically eligible; manufacturer participation rare |
| MDMA | Phase III completed | Schedule I | Theoretically eligible; sponsor willingness uncertain |
| LSD | Phase II (limited trials) | Schedule I | Meets Phase I threshold; no known willing manufacturers |
| Ayahuasca | Phase I (small studies) | Schedule I (DMT component) | Minimal investigational data; no pharmaceutical sponsor |
| Ibogaine | Phase I/II (addiction indications) | Schedule I | Cardiac safety concerns; no approved formulation or sponsor |
LSD (lysergic acid diethylamide) has Phase II data for anxiety and cluster headaches, meeting the Phase I bar. But no pharmaceutical sponsor has stepped forward to provide it under Right to Try, and the Schedule I classification complicates manufacturing and distribution even for investigational use. Understanding the distinct pharmacological profiles of psilocybin vs LSD matters clinically, but both face the same legal and supply barriers.
Ayahuasca and ibogaine have early-phase safety data but lack the institutional backing or pharmaceutical formulation needed for Right to Try. Ayahuasca contains DMT, a Schedule I substance, and no sponsor has pursued a formal investigational pathway. Ibogaine carries cardiac safety concerns and remains unscheduled in the U.S. but is similarly absent from Right to Try consideration due to lack of manufacturer engagement.
The gap between investigational eligibility and actual access is wide. Even when a psychedelic clears Phase I and has an active IND, patients depend on a manufacturer choosing to supply it, navigating DEA licensing, accepting liability, and managing informed consent and reporting. For most psychedelics, that chain of voluntary cooperation doesn’t exist yet.
Compliance, Reporting, and Manufacturer Responsibilities
Under the Right to Try Act, manufacturers bear the primary compliance burden, not patients or their physicians. These obligations center on transparency, informed consent, and annual reporting to the FDA, but they come with little federal oversight and no promise of liability protection.
The FDA’s role is deliberately narrow. The agency does not approve individual Right to Try requests, assess whether a manufacturer should grant access, or monitor ongoing safety in real time. Instead, manufacturers who supply investigational drugs under Right to Try must submit an annual summary report to the FDA. This requirement, formalized in the FDA’s final rule on annual summary reporting, exists to track aggregate use patterns and serious adverse events without creating a prior-approval bottleneck.
Submission pathways depend on the regulatory center overseeing the drug. For drugs and biological products regulated by FDA’s Center for Drug Evaluation and Research (CDER), which would include many small-molecule psychedelics and combination therapies, sponsors submit their annual summaries through the CDER NextGen Portal, an electronic submission system. For biological products regulated by the Center for Biologics Evaluation and Research (CBER), manufacturers use Form FDA 5023 and send it by email to RTTAnnualReports@fda.hhs.gov.
These reports summarize the number of patients treated, doses provided, and any serious adverse events or deaths that occurred. The data is posted publicly in anonymized form, but the FDA does not use it to halt access or sanction manufacturers unless separate safety concerns arise through other channels.
Manufacturers also assume full liability for the safety and quality of the investigational product they supply. The Right to Try Act explicitly states that neither the FDA nor the federal government shields manufacturers, sponsors, or treating physicians from lawsuits or malpractice claims. Patients must sign detailed informed consent documents acknowledging the experimental nature of the treatment, the absence of FDA review, and the potential for serious or fatal adverse effects.
Crucially, insurers are not required to cover Right to Try treatments, and most do not. Patients pay out of pocket, often facing costs in the tens of thousands of dollars for therapy, drug supply, and monitoring, costs that become prohibitive for many who qualify medically but cannot afford access.
The Practical Barriers: Cost, Geography, and Willing Providers
Even if a manufacturer agrees to supply an investigational psychedelic, patients confront steep logistical and financial hurdles. Right to Try does not require insurers to pay, and most will not cover off-label or investigational treatments, leaving the patient responsible for drug costs, clinician fees, laboratory work, and supportive therapy sessions. Out-of-pocket expenses can run into tens of thousands of dollars, especially when multiple administration sessions and integration therapy are medically necessary. For those curious about how timing affects psychedelic experiences, understanding how long shrooms last helps set realistic expectations, though this knowledge does not solve access or cost barriers.
Geography limits options further. Few manufacturers produce psychedelics at scale for compassionate or Right to Try use, and even fewer have distribution networks or clinicians trained in psychedelic-assisted therapy. Most states still classify psilocybin and MDMA as Schedule I substances with no legal medical use, creating legal risk for prescribers and patients alike. Where state laws conflict with federal Right to Try provisions, confusion persists and providers often decline participation. Meanwhile, some patients explore legal alternatives such as CBD + mushroom blends or CBD + CBG gummies though these products contain functional mushrooms and cannabinoids, not psilocybin or other scheduled psychedelics.
- Verify that your condition meets the life-threatening diagnosis requirement and that you have exhausted approved treatment options.
- Confirm the investigational psychedelic has completed Phase I safety trials and that a manufacturer is willing to supply it.
- Consult a clinician experienced in psychedelic-assisted therapy to assess medical appropriateness and provide integration support.
- Review your state’s laws on psilocybin, MDMA, and related compounds to understand legal risks.
- Secure detailed cost estimates for the drug, administration, monitoring, and follow-up therapy before committing.
Harm-reduction principles remain paramount. Psychedelics carry cardiovascular, psychiatric, and interaction risks; administration without trained supervision increases the chance of adverse outcomes. Patients who qualify under Right to Try should not proceed alone or with unvetted facilitators, and they must ensure informed consent documents disclose all known risks, contraindications, and the experimental nature of the treatment.
Where to Find Current Information and Next Steps
Start by checking the FDA’s dedicated Right to Try page, which publishes guidance documents, annual summary reports, and regulatory updates. The agency maintains current instructions for both CDER-regulated drugs (submitted through the CDER NextGen Portal) and CBER-regulated biologics (Form FDA 5023 to RTTAnnualReports@fda.hhs.gov). These resources clarify eligibility, reporting requirements, and the agency’s limited oversight role.
Use to verify a psychedelic’s investigational status. Search by compound name to confirm Phase I completion and ongoing trials. This registry shows which drugs have advanced far enough to potentially qualify under Right to Try, though manufacturer participation remains a separate hurdle.
Patient advocacy groups such as the Usona Institute, Multidisciplinary Association for Psychedelic Studies, and Heroic Hearts Project track policy developments and can connect you with legal and medical advisors familiar with psychedelic access pathways. Regional policy updates matter, too, since state laws on Schedule I substances vary widely and can block federal Right to Try permissions.
Before pursuing Right to Try, consult both a physician experienced in psychedelic-assisted therapy and a health law attorney. They can assess your eligibility, identify willing manufacturers, and navigate state-federal legal conflicts. This is not a process to start alone.
Frequently Asked Questions
Can I request psilocybin under Right to Try today?
Technically yes if you meet the eligibility criteria, a life-threatening diagnosis, exhausted approved treatments, and inability to join a clinical trial, but you need a manufacturer willing to supply psilocybin, which remains exceedingly rare as of September 2026. The April 2026 executive order directs federal agencies to establish a psychedelic Right to Try pathway, but implementation details and willing sponsors have not materialized yet.
Does the 2026 executive order change state laws?
No. The executive order directs federal agencies to facilitate access under federal Right to Try, but state laws governing controlled substances and medical practice still apply. If your state criminalizes possession or administration of psilocybin or MDMA, you could face state-level prosecution even if a federal Right to Try pathway opens.
Will insurance cover Right to Try psychedelics?
No. Right to Try is not considered standard medical care, and insurers exclude investigational therapies not approved by the FDA. Expect to pay out of pocket for the drug itself, any associated therapy sessions, monitoring, and travel if the provider is not local.
What if I don’t qualify for a clinical trial because of exclusion criteria?
Right to Try was designed for this scenario, patients who cannot access trials due to location, comorbidities, or trial enrollment caps. However, you still must meet the core eligibility threshold: a life-threatening condition and exhausted approved treatments. A diagnosis of treatment-resistant depression or PTSD alone may not qualify unless your clinician documents it as life-threatening.
How do I find a manufacturer willing to supply psychedelics under Right to Try?
Start by searching for active psilocybin or MDMA studies and noting the sponsors. Contact those companies directly to ask about their Right to Try policies; many do not have formal programs yet. Patient advocacy organizations focused on psychedelic access may also maintain lists of responsive manufacturers or connect you with others navigating the same process.
What documentation do I need to pursue Right to Try?
You will need a letter from your treating physician confirming your life-threatening diagnosis, that you have tried all FDA-approved treatments, and that you are ineligible for or unable to access a clinical trial. You also need written informed consent acknowledging the experimental nature of the therapy, potential risks, and lack of FDA approval. The manufacturer may require additional medical records or evaluations before agreeing to supply.
These answers reflect the reality as of September 2026: the legal framework exists, but the practical infrastructure, willing manufacturers, clear federal-state coordination, and clinical capacity, lags behind. The executive order signals federal intent, yet patients face uncertainty about timelines, costs, and which psychedelics will actually become accessible. If you are considering Right to Try for a psychedelic therapy, consult both a medical professional familiar with your condition and a lawyer knowledgeable about your state’s controlled substance laws. Monitor FDA updates and patient advocacy channels for emerging guidance, and prepare for a process that may take months and require significant financial and logistical resources.
The Right to Try Act offers a legal framework for accessing investigational therapies, but its promise for psychedelic treatments remains largely unrealized. While the April 2026 executive order directed federal agencies to establish a psychedelic pathway, actual patient access hinges on three critical factors: a drug’s investigational status, manufacturer willingness to supply, and evolving regulatory guidance that has yet to materialize into clear operational pathways.
Most psychedelics remain Schedule I controlled substances without completed Phase I trials or willing manufacturers, creating a gap between legal eligibility and practical availability. Even for patients with life-threatening conditions who have exhausted approved treatments, the road to psychedelic-assisted therapy under Right to Try involves navigating federal directives, state law conflicts, and significant out-of-pocket costs with no insurance coverage or liability protections.
As this landscape develops, prioritize safety and legal compliance. Monitor FDA guidance, consult medical and legal professionals, and connect with patient advocacy organizations tracking psychedelic policy. The executive order signals intent, but meaningful access requires manufacturer participation, clear compliance protocols, and trained providers, elements still taking shape as of September 2026. Stay informed, advocate for transparent implementation timelines, and approach any investigational treatment with rigorous informed consent and therapeutic support.